Acelyrin's 2024 comeback is picking up speed, as the biotech presents proof-of-concept data on a thyroid eye disease (TED) treatment just over a week after two other positive trial updates.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,